Effect of erythromycin on the absorption of fexofenadine in the jejunum, ileum and colon determined using local intubation in healthy volunteers

International Journal of Clinical Pharmacology and Therapeutics

Volumn 44, Issue 2, 2006, Pages 71-79

  Petri, N ^a   Borga, O ^b   Nyberg, L ^b   Hedeland, M ^a   Bondesson, U ^a   Lennernas, Hans ^a  

^a UPPSALA UNIVERSITY   (Sweden)

^b Bioperm AB   (Sweden)

Author keywords

ABCB1; Erythromycin; Fexofenadine; OATP; Regional absorption

Indexed keywords

ABBOTICIN; ERYTHROMYCIN LACTOBIONATE; FEXOFENADINE; METOCLOPRAMIDE;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; COLON; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIET RESTRICTION; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG PENETRATION; DRUG TRANSPORT; FEMALE; HUMAN; HUMAN EXPERIMENT; ILEUM; IN VIVO STUDY; INTESTINE ABSORPTION; INTESTINE MOTILITY; INTUBATION; JEJUNUM; MALE; NORMAL HUMAN; OPEN STUDY; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; VOLUNTEER;

EID: 32544442324     PISSN: 09461965     EISSN: None     Source Type: Journal    
DOI: 10.5414/CPP44071     Document Type: Article

References (38)

1. Abrahamsson B, Lindström K, Nyberg L, Pettersson A, Sunzel M, Ungell AL, Mansson W. Regional absorption of metoprolol in humans determined by a new method suitable for studies in the whole gastro-intestinal tract. [Abstract]. CRS 24th Int Symposium on Controlled Release of Bioactive Materials. Stockholm, June 15-19; 1997.
2. Berggren S, Lennernas P, Ekelund M, Westrom B, Hoogstraate J, Lennernas H. Regional transport and metabolism of ropivacaine and its CYP3A4 metabolite PPX in human intestine. J Pharm Pharmacol. 2003; 55: 963-972.
3. CDER. Clinical pharmacology/biopharmaceutics review: Allegra (Fexofenadine Hydrochloride) Tablets Application No.: 20-872, FDA, CDER; 2000.
4. Chadwick VS, Phillips SF, Hofmann AF. Measurements of intestinal permeability using low molecular weight polyethylene glycols (PEG 400). II. Application to normal and abnormal permeability states in man and animals. Gastroenterology. 1977; 73: 247-251.
5. Cremonini F, Mullan BP, Camilleri M, Burton DD, Rank MR. Performance characteristics of scintigraphic transit measurements for studies of experimental therapies. Aliment Pharmacol Ther. 2002; 16: 1781-1790.
6. Cvetkovic M, Leake B, Fromm MF, Wilkinson GR, Kim RB. OATP and P-glycoprotein transporters mediate the cellular uptake and excretion of fexofenadine. Drug Metab Dispos. 1999; 27: 866-871.
7. Davit B, Reynolds K, Yuan R, Ajayi F, Conner D, Fadiran E, Gillespie B, Sahajwalla C, Huang SM, Lesko LJ. FDA evaluations using in vitro metabolism to predict and interpret in vivo metabolic drug-drug interactions: impact on labeling. J Clin Pharmacol. 1999; 39: 899-910.
8. Dresser GK, Bailey DG, Leake BF, Schwarz UI, Dawson PA, Freeman DJ, Kim RB. Fruit juices inhibit organic anion transporting polypeptide-mediated drug uptake to decrease the oral availability of fexofenadine. Clin Pharmacol Ther. 2002; 71: 11-20.
9. Dresser GK, Kim RB, Bailey DG. Effect of grapefruit juice volume on the reduction of foxofenadine bioavailability: possible role of organic anion transporting polypeptides. Clin Pharmacol Ther. 2005; 77: 170-177.
10. Fagerholm U, Lindahl A, Lennernas H. Regional intestinal permeability in rats of compounds with different physicochemical properties and transport mechanisms. J Pharm Pharmacol. 1997; 49: 687-690.
11. Hamman MA, Bruce MA, Haehner-Daniels BD, Hall SD. The effect of rifampin administration on the disposition of fexofenadine. Clin Pharmacol Ther. 2001; 69: 114-121.
12. Kelder J, Grootenhuis PD, Bayada DM, Delbressine LP, Ploemen JP. Polar molecular surface as a dominating determinant for oral absorption and brain penetration of drugs. Pharm Res. 1999; 16: 1514-1519.
13. Koboyashi D, Nozawa T, Imai K, Nezu J, Tsuji A, Tamai I. Involvement of human organic anion transporting polypeptide OATP-B (SLC21A9) in pH-dependent transport across intestinal apical membrane. J Pharmacol Exp Ther. 2003; 306: 703-708.
14. Kullak-Ublick GA, Ismair MG, Stieger B, Landmann L, Huber R, Pizzagalli F, Fattinger K, Meier PJ, Hagenbuch B. Organic anion-transporting polypeptide B (OATP-B) and its functional comparison with three other OATPs of human liver. Gastroenterology. 2001; 120: 525-533.
15. Lande MB, Priver NA, Zeidel ML. Determinants of apical membrane permeabilities of barrier epithelia. Am J Physiol. 1994; 267: C367-C374.
16. Lippert C, Ling J, Brown P, Burmaster S, Eller M, Cheng L, Thompson R, Weir S. Mass balance and pharmacokinetics of MDL 16,455A in healthy male volunteers. Pharm Res. 1999; 12: S390.
17. Mouly S, Paine MF. P-glycoprotein increases from proximal to distal regions of human small intestine. Pharm Res. 2003; 20: 1595-1599.
18. Nakamura T, Sakaeda T, Ohmoto N, Tamura T, Aoyama N, Shirakawa T, Kamigaki T, Kim KI, Kim SR, Kuroda Y, Matsuo M, Kasuga M, Okumura K. Real-time quantitative polymerase chain reaction for MDR1, MRP1, MRP2, and CYP3A-mRNA levels in Caco-2 cell lines, human duodenal enterocytes, normal colorectal tissues, and colorectal adenocarcinomas. Drug Metab Dispos. 2002; 30: 4-6.
19. Naslund E, Bogefors J, Gryback P, Jacobsson H, Hellstrom PM. Gastric emptying: comparison of scintigraphic, polyethylene glycol dilution, and paracetamol tracer assessment techniques. Scand J Gastroenterol. 2000; 35: 375-379.
20. Niemi M, Kivisto KT, Hofmann U, Schwab M, Eichelbaum M, Fromm MF. Fexofenadine pharmacokinetics are associated with a polymorphism of the SLCO1B1 gene (encoding OATP1B1). Br J Clin Pharmacol. 2005; 59: 602-604.
21. Nozawa T, Imai K, Nezu J, Tsuji A, Tamai I. Functional characterization of pH-sensitive organic anion transporting polypeptide OATP-B in human. J Pharmacol Exp Ther. 2004; 308: 438-445.
22. Perloff MD, von Moltke LL, Greenblatt DJ. Fexofenadine transport in Caco-2 cells: inhibition with verapamil and ritonavir. J Clin Pharmacol. 2002; 42: 1269-1274.
23. Petri N, Tannergren C, Rungstad D, Lennernas H. Transport characteristics of fexofenadine in the Caco-2 cell model. Pharm Res. 2004; 21: 1398-1404.
24. Polli JW, Wring SA, Humphreys JE, Huang L, Morgan JB, Webster LO, Serabjit-Singh CS. Rational use of in vitro P-glycoprotein assays in drug discovery. J Pharmacol Exp Ther. 2001; 299: 620-628.
25. Read NW, Al Janabi MN, Bates TE, Barber DC. Effect of gastrointestinal intubation on the passage of a solid meal through the stomach and small intestine in humans. Gastroenterology. 1983; 84: 1568-1572.
26. Shimizu M, Fuse K, Okudaira K, Nishigaki R, Maeda K, Kusuhara H, Sugiyama Y. Contribution of OATP family transporters to the hepatic uptake of fexofenadine in humans. Drug Metab Dispos. 2005; 33: 1477-1481.
27. Smith LH, Lee W, Kim RB. Differential expression of OATP drug uptake transporters in human liver, intestine and kidney. Drug Metab Rev. 2003; 35: 73.
28. Somogyi AA, Bochner F, Hetzel D, Williams DB. Evaluation of the intestinal absorption of erythromycin in man: absolute bioavailability and comparison with enteric coated erythromycin. Pharm Res. 1995; 12: 149-154.
29. Tamai I, Nezu J, Uchino H, Sai Y, Oku A, Shimane M, Tsuji A. Molecular identification and characterization of novel members of the human organic anion transporter (OATP) family. Biochem Biophys Res Commun. 2000; 273: 251-260.
30. Tannergren C, Knutson T, Knutson L, Lennernas H. The effect of ketoconazole on the in vivo intestinal permeability of fexofenadine using a regional perfusion technique. Br J Clin Pharmacol. 2003a; 55: 182-190.
31. Tannergren C, Petri N, Knutson L, Hedeland M, Bondesson U, Lennernas H. Multiple transport mechanisms involved in the intestinal absorption and first-pass extraction of fexofenadine. Clin Pharmacol Ther. 2003b; 74: 423-436.
32. Thorn M, Finnstrom N, Lundgren S, Rane A, Loof L. Cytochrome P450 and MDR1 mRNA expression along the human gastrointestinal tract. Br J Clin Pharmacol. 2005; 60: 54-60.
33. Ungell AL, Nylander S, Bergstrand S, Sjoberg A, Lennernas H. Membrane transport of drugs in different regions of the intestinal tract of the rat. J Pharm Sci. 1998; 87: 360-366.
34. Wang Z, Hamman MA, Huang SM, Lesko LJ, Hall SD. Effect of St John's wort on the pharmacokinetics of fexofenadine. Clin Pharmacol Ther. 2002; 71: 414-420.
35. Wilding I, Prior D. Remote controlled capsules in human drug absorption (HDA) studies. Crit Rev Ther Drug Carrier Syst. 2003; 20: 405-431.
36. Wilson JP. Surface area of the small intestine in man. Gut. 1967; 8: 618-621.
37. Winiwarter S, Bonham NM, Ax F, Hallberg A, Lennernas H, Karlen A. Correlation of human jejunal permeability (in vivo) of drugs with experimentally and theoretically derived parameters. A multivariate data analysis approach. J Med Chem. 1998; 41: 4939-4949.
38. Yasui-Furukori N, Uno T, Sugawara K, Tateishi T. Different effects of three transporting inhibitors, verapamil, cimetidine, and probenecid, on fexofenadine pharmacokinetics. Clin Pharmacol Ther. 2005; 77: 17-23.